Polaryx Therapeutics, Inc.
PLYX Nasdaq
SEC CIK 2075320
Follow Polaryx Therapeutics
Weekly email: filings, results
Net income
−$3.3M
−132.7% vs same quarter last year
EPS, diluted
−$0.07
−133.3% vs same quarter last year
Operating cash flow
−$3.1M
−249.7% vs same quarter last year
Operating income
−$3.3M
−241.7% vs same quarter last year
Source: SEC XBRL filings · latest filing